Page 1

Biocept Completing the Answer ™ Biocept Reports Second Quarter 2021 Financial Results August 16 , 2021 • Second quarter revenues of $ 12.0 million driven by RT - PCR COVID - 19 testing • Continued sequential - quarter CNSide TM volume growth with customer base expanding to more than 30 leadingU.S . academic institutions , including multiple repeat users • Issued coverage with high - value payment by Medicare for the Target Selector TM breast cancer assay to detect the HER2 biomarker • Received nearly 500,000 samples for COVID - 19 RT - PCR testing since June 2020 Conference call begins at 4:30 p.m. Eastern time today SAN DIEGO -- ( BUSINESS WIRE ) -- Aug . 16 , 2021-- Biocept . Inc. ( Nasdaq : BIOC ) , a leading provider of molecular diagnostic assays , products and services , reports financial results for the three and six months ended June 30 , 2021 and provides a business update . " We are reporting profitability for the first half of 2021 on revenues of nearly $ 30 million driven by RT - PCR COVID - 19 testing , " said Michael Nall , Biocept's President and CEO . " Revenues of $ 12.0 million for the quarter reflect the anticipated sequential quarter decline in COVID - 19 testing as more Americans became vaccinated . That said , COVID - 19 testing volume in the current quarter is presently running at a higher rate than second quarter levels largely due to the Delta variant with more than 50,000 samples received in the past month as we near the 500,000 sample milestone . We are prepared for increases in COVID - 19 testing volume in the coming weeks as we begin receiving samples from California community college students returning to in - person classes . " We are encouraged by the ongoing adoption of our paradigm - changing neuro - oncology CNSide assay , which provides physicians with a valuable tool to diagnose and manage patients with tumors that have metastasized to the central nervous system , " he added . " CNSide volume has grown each consecutive quarter since our beta launch in early 2020. We have now received orders from more than 30 leading U.S. academic institutions with the majority becoming repeat customers . Importantly , we have seen CNSide positively impact the life expectancy and the quality of life of patients who otherwise might be referred to hospice care . " Finally , we are pleased with Medicare's decision to provide coverage and high - value payment for our Target Selector breast cancer assay that detects the HER2 biomarker . Testing for the HER2 biomarker is among the most important sources of information when making treatment decisions for patients diagnosed with breast cancer and is an our most frequently ordered assay profiles , " concluded Mr. Nall . Second Quarter 2021 and Recent Highlights Commercial Developments and Agreements Oncology • Announced a positive coverage decision from Medicare and high - value reimbursement of $ 2,435 for the Target Selector breast cancer assay to detect the HER2 biomarker from circulating tumor cells ( CTCs ) in liquid biopsy . The coverage decision became effective July 4 , 2021 . • Expanded the company's relationship with Quest Diagnostics to provide patients across the U.S. with access to the Target Selector NGS lung assay . Biocept anticipates that Quest's specialized oncology salesforce will begin marketing this Target Selector panel in the fourth quarter of 2021 . • Expanded the customer base for CNSide to more than 30 top U.S. academic institutions with the majority as repeat customers . CNSide is Biocept's cerebrospinal fluid assay that offers a timely and accurate method to diagnose patients with lung and breast cancer that has metastasized to the central nervous system , along with the ability to identify actionable biomarkers and assess a patient's response to therapy . COVID - 19 ● Signed an agreement to make Biocept's COVID - 19 testing available to the more than 2.1 million students , as well as faculty and staff of the California community colleges . The availability of COVID - 19 testing is expected to provide information to help protect the safety of campus populations and reduce the spread of the SARS - CoV - 2 virus as students return to campus . • Coordinated with CLEARED4 to develop and implement a system to streamline testing protocols and track COVID - 19 testing results . The system is intended to help Biocept customers , including California community colleges , ease the